Nancy R Cook

List of Publications by Year
in descending order

170 papers	32,688 citations	22153 59 h-index	5988 160 g-index
179 all docs	179 docs citations	179 times ranked	36972 citing authors

#	Article	IF	Citations
1	Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 525-537.	3.6	4
2	Effect of vitamin D supplementation on urinary incontinence in older women: ancillary findings from a randomized trial. American Journal of Obstetrics and Gynecology, 2022, 226, 535.e1-535.e12.	1.3	7
3	Geographic Region, Racial/Ethnic Disparities, and Late-Life Depression: Results From a Large US Cohort of Older Adults. American Journal of Geriatric Psychiatry, 2022, 30, 703-716.	1.2	1
4	24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk. New England Journal of Medicine, 2022, 386, 252-263.	27.0	140
5	Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ, The, 2022, 376, e066452.	6.0	177
6	Sodium and Health: Old Myths and a Controversy Based on Denial. Current Nutrition Reports, 2022, 11, 172-184.	4.3	32
7	Association of Modifiable Lifestyle Factors with Plasma Branched-Chain Amino Acid Metabolites in Women. Journal of Nutrition, 2022, 152, 1515-1524.	2.9	6
8	Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1501-1510.	4.7	17
9	Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1490-1500.	4.7	71
10	Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of HeartÂFailure Hospitalization. JACC: Heart Failure, 2022, 10, 227-234.	4.1	8
11	Arrhythmic sudden death survival prediction using deep learning analysis of scarring in the heart. , 2022, 1, 334-343.		43
12	Historical Controls in Randomized Clinical Trials: Opportunities and Challenges. Clinical Pharmacology and Therapeutics, 2021, 109, 343-351.	4.7	15
13	Validation of electrocardiographic criteria for identifying left ventricular dysfunction in patients with previous myocardial infarction. Annals of Noninvasive Electrocardiology, 2021, 26, e12812.	1.1	6
14	Effects of Vitamin D3 Supplementation on Body Composition in the VITamin D and OmegA-3 TriaL (VITAL). Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1377-1388.	3.6	18
15	Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2021, 325, 1061.	7.4	73
16	Abstract 019: Modifiable Lifestyle Factors And Plasma Branched Chain Amino Acids: An Analysis Of N=19,472 US Women. Circulation, 2021, 143, .	1.6	1
17	Dose-Response Models May Explain Age-Related Macular Degeneration and Vitamin Treatmentsâ€"Reply. JAMA Ophthalmology, 2021, 139, 677.	2.5	0
18	Effect of Vitamin D and/or Marine n-3 Fatty Acid Supplementation on Changes in Migraine Frequency and Severity. American Journal of Medicine, 2021, 134, 756-762.e5.	1.5	6

#	ARTICLE	IF	CITATIONS
19	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal, 2021, 42, 2439-2454.	2.2	491
20	Diabetes and Risk of Sudden Death in Coronary Artery Disease Patients Without Severe Systolic Dysfunction. JACC: Clinical Electrophysiology, 2021, 7, 1604-1614.	3.2	4
21	Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. Circulation Genomic and Precision Medicine, 2021, 14, e003330.	3.6	19
22	Effect of Long-Term Marine É·-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation, 2021, 144, 1981-1990.	1.6	59
23	1102â€¦Fish oil supplementation and pro-inflammatory and pro-resolving lipid mediators in patients with and without systemic lupus erythematosus. , 2021, , .		1
24	Abstract 11848: Biomarkers of Glucose-Insulin Homeostasis, Randomized Treatment With Omega-3 and Vitamin D Supplementation, and Incident Type 2 Diabetes: Prospective Analysis From the Vitamin D and Omega-3 Trial (VITAL). Circulation, 2021, 144, .	1.6	0
25	Marine nâ€3 fatty acids and cognitive change among older adults in the VITAL randomized trial. Alzheimer's and Dementia, 2021, 17, .	0.8	1
26	Abstract 12860: Effects of Marine Omega-3 and Vitamin D Supplementation on Circulating Biomarkers of Glucose-Insulin Homeostasis and Incident Cardiovascular Disease in the Vitamin D and Omega-3 Trial (VITAL). Circulation, 2021, 144, .	1.6	0
27	Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization. Circulation, 2020, 141, 784-786.	1.6	41
28	Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA-3 TriaL (VITAL). Journal of Bone and Mineral Research, 2020, 35, 883-893.	2.8	69
29	Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. Circulation Research, 2020, 126, 112-128.	4.5	45
30	Evidence-Based Policy Making for Public Health Interventions in Cardiovascular Diseases: Formally Assessing the Feasibility of Clinical Trials. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006378.	2.2	5
31	Effect of Vitamin D_3 Supplements on Development of Advanced Cancer. JAMA Network Open, 2020, 3, e2025850.	5.9	158
32	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. JACC: CardioOncology, 2020, 2, 400-410.	4.0	8
33	Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death. Circulation, 2020, 142, 1148-1158.	1.6	19
34	Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials. JAMA Network Open, 2020, 3, e2013196.	5.9	27
35	Effect of Vitamin D and Ï‰-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration. JAMA Ophthalmology, 2020, 138, 1280.	2.5	20
36	VITamin D and OmegA-3 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US Population. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2929-2938.	3.6	58

#	Article	IF	Citations
37	Association of Race and Ethnicity With Late-Life Depression Severity, Symptom Burden, and Care. JAMA Network Open, 2020, 3, e201606.	5.9	44
38	Simple electrocardiographic measures improve sudden arrhythmic death prediction in coronary disease. European Heart Journal, 2020, 41, 1988-1999.	2.2	33
39	The Effects of Vitamin D and Marine Omega‐3 Fatty Acid Supplementation on Chronic Knee Pain in Older US Adults: Results From a Randomized Trial. Arthritis and Rheumatology, 2020, 72, 1836-1844.	5.6	28
40	Sodium and health—concordance and controversy. BMJ, The, 2020, 369, m2440.	6.0	54
41	Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL. Journal of Clinical Lipidology, 2020, 14, 241-251.	1.5	17
42	Estimating Myocardial Infarction Size With a Simple Electrocardiographic Marker Score. Journal of the American Heart Association, 2020, 9, e014205.	3.7	17
43	Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. Journal of the American College of Cardiology, 2020, 75, 2122-2135.	2.8	160
44	Abstract 13479: Association of Plasma Branched Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. Circulation, 2020, 142, .	1.6	1
45	Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. Journal of the National Cancer Institute, 2019, 111, 158-169.	6.3	199
46	Prospectively collected lifestyle and health information as risk factors for white matter hyperintensity volume in stroke patients. European Journal of Epidemiology, 2019, 34, 957-965.	5.7	8
47	Formulas to Estimate Dietary Sodium Intake From Spot Urine Alter Sodium-Mortality Relationship. Hypertension, 2019, 74, 572-580.	2.7	70
48	Incorporation of a Molecular Prognostic Classifier Improves Conventional Non‐Small Cell Lung Cancer Staging. Journal of Thoracic Oncology, 2019, 14, 1223-1232.	1.1	20
49	Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical Chemistry, 2019, 65, 1508-1521.	3.2	23
50	Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment. Contemporary Clinical Trials, 2019, 87, 105854.	1.8	24
51	Statistical methods for building better biomarkers of chronic kidney disease. Statistics in Medicine, 2019, 38, 1903-1917.	1.6	7
52	COMT Effects on Vitamin E and Colorectal Cancer, in-vitro and in Two Randomized Trials (P15-005-19). Current Developments in Nutrition, 2019, 3, nzz037.P15-005-19.	0.3	2
53	Racial Variation in Stroke Risk Among Women by Stroke Risk Factors. Stroke, 2019, 50, 797-804.	2.0	24
54	Response to: Errors in application of the Kawasaki formula to estimate sodium intake, and false interpretation of data, misclassify the relationship of sodium intake with mortality. International Journal of Epidemiology, 2019, 48, 1019-1020.	1.9	0

#	Article	IF	Citations
55	Comparison of 24‑hour urine and 24‑hour diet recall for estimating dietary sodium intake in populations: A systematic review and meta‑analysis. Journal of Clinical Hypertension, 2019, 21, 1753-1762.	2.0	35
56	Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open, 2019, 2, e1917062.	5.9	11
57	Design and analysis considerations for combining data from multiple biomarker studies. Statistics in Medicine, 2019, 38, 1303-1320.	1.6	10
58	Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. European Heart Journal, 2019, 40, 621-631.	2.2	97
59	Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine, 2019, 380, 33-44.	27.0	1,141
60	Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. New England Journal of Medicine, 2019, 380, 23-32.	27.0	684
61	COMT and Alpha-Tocopherol Effects in Cancer Prevention: Gene-Supplement Interactions in Two Randomized Clinical Trials. Journal of the National Cancer Institute, 2019, 111, 684-694.	6.3	24
62	Vitamin D and Omega-3 Fatty Acid Trial 2017: Addressing Effects on Muscle and Bone. , 2019, , 11-23.		0
63	Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL): Effects on Bone Structure and Architecture. Contemporary Clinical Trials, 2018, 67, 56-67.	1.8	12
64	Metabolic Predictors of Incident Coronary Heart Disease in Women. Circulation, 2018, 137, 841-853.	1.6	177
65	Racial Variation in Total Knee Replacement in a Diverse Nationwide Clinical Trial. Journal of Clinical Rheumatology, 2018, 24, 1-5.	0.9	33
66	Sudden Death in Patients With Coronary Heart Disease Without Severe Systolic Dysfunction. JAMA Cardiology, 2018, 3, 591.	6.1	40
67	The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression. Contemporary Clinical Trials, 2018, 68, 133-145.	1.8	34
68	Prospective study of plasma homocysteine, its dietary determinants, and risk of age-related macular degeneration in men. Ophthalmic Epidemiology, 2018, 25, 79-88.	1.7	15
69	Homocysteine, B Vitamins, MTHFR Genotype, and Incident Age-Related Macular Degeneration. Ophthalmology Retina, 2018, 2, 508-510.	2.4	3
70	Twenty‑Four‑Hour Diet recall and Diet records compared with 24‑hour urinary excretion to predict an individual's sodium consumption: A Systematic Review. Journal of Clinical Hypertension, 2018, 20, 1360-1376.	2.0	60
71	Weight change and mortality: Long‑term results from the trials of hypertension prevention. Journal of Clinical Hypertension, 2018, 20, 1666-1673.	2.0	12
72	Meta-analysis of LDL-C Lowering and Mortality. JAMA - Journal of the American Medical Association, 2018, 320, 1493.	7.4	0

#	Article	IF	Citations
73	Hypertensive Disorders of Pregnancy and 10-Year Cardiovascular Risk Prediction. Journal of the American College of Cardiology, 2018, 72, 1252-1263.	2.8	97
74	Reclassification calibration test for censored survival data: performance and comparison to goodness-of-fit criteria. Diagnostic and Prognostic Research, 2018, 2, .	1.8	5
75	Quantifying the added value of new biomarkers: how and how not. Diagnostic and Prognostic Research, 2018, 2, 14.	1.8	108
76	Effect of Combined Treatment With Folic Acid, Vitamin B $_6$, and Vitamin B $_{12}$ on Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women. Journal of the American Heart Association, 2018, 7, .	3.7	31
77	Errors in estimating usual sodium intake by the Kawasaki formula alter its relationship with mortality: implications for public health€. International Journal of Epidemiology, 2018, 47, 1784-1795.	1.9	71
78	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women€™s Health Initiative. JAMA Internal Medicine, 2018, 178, 1231.	5.1	58
79	Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. Journal of the American College of Cardiology, 2018, 72, 287-296.	2.8	73
80	Association between Vitamin D Genetic Risk Score and Cancer Risk in a Large Cohort of U.S. Women. Nutrients, 2018, 10, 55.	4.1	22
81	Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet, The, 2018, 392, 387-399.	13.7	273
82	Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. Circulation, 2018, 138, 2330-2341.	1.6	98
83	Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?. European Heart Journal, 2017, 38, ehw287.	2.2	17
84	A new community for those involved and interested in diagnosis and prognosis. Diagnostic and Prognostic Research, 2017, 1, 5.	1.8	1
85	Serum Sortilin Associates With Aortic Calcification and Cardiovascular Risk in Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1005-1011.	2.4	44
86	Cholesterol Evaluation in Young Adults: Absence of Clinical Trial Evidence Is Not a Reason to Delay Screening. Annals of Internal Medicine, 2017, 166, 901.	3.9	5
87	Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women. Journal of the Endocrine Society, 2017, 1, 113-123.	0.2	16
88	Modifiable Risk Factors for Incident HeartÂFailure in Atrial Fibrillation. JACC: Heart Failure, 2017, 5, 552-560.	4.1	58
89	Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20Âyears: The Women's Health Study. Journal of Clinical Lipidology, 2017, 11, 1257-1267.e2.	1.5	40
90	Assessment of dietary sodium intake using a food frequency questionnaire and 24â€hour urinary sodium excretion: a systematic literature review. Journal of Clinical Hypertension, 2017, 19, 1214-1230.	2.0	92

#	Article	IF	Citations
91	Clinical risk reclassification at 10 years. Statistics in Medicine, 2017, 36, 4498-4502.	1.6	10
92	Asymptotic distribution of â^†AUC, NRIs, and IDI based on theory of Uâ€statistics. Statistics in Medicine, 2017, 36, 3334-3360.	1.6	20
93	Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease. Circulation, 2017, 135, 566-577.	1.6	231
94	Hemoglobin A1c levels and risk of sudden cardiac death: A nested case-control study. Heart Rhythm, 2017, 14, 72-78.	0.7	14
95	Adding tests to risk based guidelines: evaluating improvements in prediction for an intermediate risk group. BMJ, The, 2016, 354, i4450.	6.0	6
96	Calibration and seasonal adjustment for matched caseâ€"control studies of vitamin D and cancer. Statistics in Medicine, 2016, 35, 2133-2148.	1.6	28
97	Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease. Annals of Internal Medicine, 2016, 165, 786.	3.9	120
98	The Pooled Cohort Equations 3 Years On. Circulation, 2016, 134, 1789-1791.	1.6	34
99	Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. JAMA Cardiology, 2016, 1, 389.	6.1	150
100	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes and Endocrinology,the, 2016, 4, 840-849.	11.4	159
101	Sodium Intake and All-Cause Mortality Over 20 Years in the Trials of HypertensionÂPrevention. Journal of the American College of Cardiology, 2016, 68, 1609-1617.	2.8	173
102	Vitamin D and Omega-3 Fatty Acids and Bone Health: Ancillary Studies in the VITAL Randomized Controlled Trial. , 2016, , 217-226.		0
103	Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. New England Journal of Medicine, 2016, 375, 2349-2358.	27.0	979
104	How to translate clinical trial results into gain in healthy life expectancy for individual patients. BMJ, The, 2016, 352, i1548.	6.0	44
105	Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy. American Journal of Cardiology, 2016, 118, 49-55.	1.6	5
106	Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL). Contemporary Clinical Trials, 2016, 47, 235-243.	1.8	91
107	Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. American Journal of Cardiology, 2016, 117, 376-381.	1.6	10
108	Comparison of Self-Reported and Accelerometer-Assessed Physical Activity in Older Women. PLoS ONE, 2015, 10, e0145950.	2.5	47

#	Article	IF	Citations
109	Tests of calibration and goodnessâ€ofâ€fit in the survival setting. Statistics in Medicine, 2015, 34, 1659-1680.	1.6	216
110	Adiposity Throughout Adulthood and RiskÂof Sudden Cardiac Death in Women. JACC: Clinical Electrophysiology, 2015, 1, 520-528.	3.2	24
111	VITAL-Bone Health: Rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA-3 TriaL (VITAL). Contemporary Clinical Trials, 2015, 41, 259-268.	1.8	43
112	A Proposal to Incorporate Trial Data Into aÂHybrid ACC/AHA Algorithm forÂthe Allocation of Statin Therapy in Primary Prevention. Journal of the American College of Cardiology, 2015, 65, 942-948.	2.8	21
113	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. Clinical Chemistry, 2015, 61, 1156-1163.	3.2	53
114	Prospective Study of Plasma Homocysteine Level and Risk of Age-Related Macular Degeneration in Women. Ophthalmic Epidemiology, 2015, 22, 85-93.	1.7	12
115	Effect of long-term supplementation with folic acid and B vitamins on risk of depression in older women. British Journal of Psychiatry, 2015, 206, 324-331.	2.8	44
116	Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart, 2015, 101, 369-376.	2.9	41
117	Response to Letter Regarding Article, â€œLower Levels of Sodium Intake and Reduced Cardiovascular Riskâ€. Circulation, 2014, 130, e269.	1.6	2
118	Response to Comment on the Reports of Over-estimation of ASCVD Risk Using the 2013 AHA/ACC Risk Equation. Circulation, 2014, 129, 268-269.	1.6	18
119	Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies. American Journal of Epidemiology, 2014, 179, 621-632.	3.4	47
120	Lifestyleâ€Based Prediction Model for the Prevention of CVD: The Healthy Heart Score. Journal of the American Heart Association, 2014, 3, e000954.	3.7	85
121	Further Insight Into the Cardiovascular Risk Calculator. JAMA Internal Medicine, 2014, 174, 1964.	5.1	148
122	B-Type Natriuretic Peptides Improve Cardiovascular Disease Risk Prediction in a Cohort of Women. Journal of the American College of Cardiology, 2014, 64, 1789-1797.	2.8	25
123	Lower Levels of Sodium Intake and Reduced Cardiovascular Risk. Circulation, 2014, 129, 981-989.	1.6	219
124	Refining the American guidelines for prevention of cardiovascular disease â€“ Authors' reply. Lancet, The, 2014, 383, 600.	13.7	47
125	Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial. Annals of Internal Medicine, 2013, 159, 77.	3.9	264
126	Net reclassification improvement: a link between statistics and clinical practice. European Journal of Epidemiology, 2013, 28, 21-23.	5.7	9

#	Article	IF	Citations
127	A Bias-Corrected Net Reclassification Improvement for Clinical Subgroups. Medical Decision Making, 2013, 33, 154-162.	2.4	34
128	Clinically Relevant Measures of Fit? A Note of Caution. American Journal of Epidemiology, 2012, 176, 488-491.	3.4	37
129	Clinical Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Disease Prediction in a Multiethnic Cohort of Women. Clinical Chemistry, 2012, 58, 1352-1363.	3.2	27
130	The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials, 2012, 33, 159-171.	1.8	477
131	Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative. Circulation, 2012, 125, 1748-1756.	1.6	205
132	Comments on â€˜Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersâ€™ by M. J. Pencina, R. B. D'Agostino, Sr. and E. W. Steyerberg. Statistics in Medicine, 2012, 31, 93-95.	1.6	20
133	Aspirin in the primary prevention of cardiovascular disease in the Womenâ€™s Health Study: Effect of noncompliance. European Journal of Epidemiology, 2012, 27, 431-438.	5.7	13
134	Performance of reclassification statistics in comparing risk prediction models. Biometrical Journal, 2011, 53, 237-258.	1.0	97
135	Assessing the Incremental Role of Novel and Emerging Risk Factors. Current Cardiovascular Risk Reports, 2010, 4, 112-119.	2.0	37
136	Assessing the Performance of Prediction Models. Epidemiology, 2010, 21, 128-138.	2.7	3,387
137	Mammographic Screening and Risk Factors for Breast Cancer. American Journal of Epidemiology, 2009, 170, 1422-1432.	3.4	50
138	Joint Effects of Sodium and Potassium Intake on Subsequent Cardiovascular Disease. Archives of Internal Medicine, 2009, 169, 32.	3.8	348
139	A Common Variant at 9p21 Is Associated With Sudden and Arrhythmic Cardiac Death. Circulation, 2009, 120, 2062-2068.	1.6	67
140	Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein as Predictors of Sudden Cardiac Death Among Women. Circulation, 2009, 119, 2868-2876.	1.6	62
141	Using Relative Utility Curves to Evaluate Risk Prediction. Journal of the Royal Statistical Society Series A: Statistics in Society, 2009, 172, 729-748.	1.1	120
142	Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures. Annals of Internal Medicine, 2009, 150, 795.	3.9	416
143	Comments on â€˜Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyondâ€™ by M. J. Pencina et al., Statistics in Medicine (DOI:) Tj ETQq1 1 0.784314 rgBT /Overl	35
144	Statistical Evaluation of Prognostic versus Diagnostic Models: Beyond the ROC Curve. Clinical Chemistry, 2008, 54, 17-23.	3.2	603

#	ARTICLE	IF	CITATIONS
145	Salt intake, blood pressure and clinical outcomes. Current Opinion in Nephrology and Hypertension, 2008, 17, 310-314.	2.0	26
146	Response to Letters Regarding Article, "Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction". Circulation, 2007, 116, .	1.6	6
147	Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ: British Medical Journal, 2007, 334, 885.	2.3	974
148	Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women. JAMA - Journal of the American Medical Association, 2007, 297, 611.	7.4	1,529
149	A Randomized Factorial Trial of Vitamins C and E and Beta Carotene in the Secondary Prevention of Cardiovascular Events in Women. Archives of Internal Medicine, 2007, 167, 1610.	3.8	408
150	Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction. Circulation, 2007, 115, 928-935.	1.6	1,773
151	The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women. Annals of Internal Medicine, 2006, 145, 21.	3.9	445
152	Excess Deaths Associated With Underweight, Overweight, and Obesity. JAMA - Journal of the American Medical Association, 2005, 293, 1861.	7.4	2,283
153	Low-Dose Aspirin in the Primary Prevention of Cancer. JAMA - Journal of the American Medical Association, 2005, 294, 47.	7.4	704
154	A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. New England Journal of Medicine, 2005, 352, 1293-1304.	27.0	1,801
155	Tree and spline based association analysis of gene–gene interaction models for ischemic stroke. Statistics in Medicine, 2004, 23, 1439-1453.	1.6	139
156	Using the area under the curve to reduce measurement error in predicting young adult blood pressure from childhood measures. Statistics in Medicine, 2004, 23, 3421-3435.	1.6	56
157	Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. New England Journal of Medicine, 2002, 347, 1557-1565.	27.0	3,201
158	Use of a Marginal Structural Model to Determine the Effect of Aspirin on Cardiovascular Mortality in the Physicians' Health Study. American Journal of Epidemiology, 2002, 155, 1045-1053.	3.4	91
159	Migraine and Coronary Heart Disease in Women and Men. Headache, 2002, 42, 715-727.	3.9	74
160	Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians' Health Study. Archives of Internal Medicine, 2000, 160, 921.	3.8	24
161	Combining annual blood pressure measurements in childhood to improve prediction of young adult blood pressure. Statistics in Medicine, 2000, 19, 2625-2640.	1.6	18
162	Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes and Control, 2000, 11, 617-626.	1.8	143

#	Article	IF	Citations
163	A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis and Rheumatism, 1999, 42, 910-917.	6.7	217
164	Adult height and incidence of cancer in male physicians (United States). Cancer Causes and Control, 1997, 8, 591-597.	1.8	86
165	An imputation method for non-ignorable missing data in studies of blood pressure. , 1997, 16, 2713-2728.		17
166	Ten-Year Institutional Experience With Palliative Surgery for Hypoplastic Left Heart Syndrome. Circulation, 1995, 92, 262-266.	1.6	169
167	Height, Lung Function, and Mortality from Cardiovascular Disease among the Elderly. American Journal of Epidemiology, 1994, 139, 1066-1076.	3.4	57
168	Childhood blood pressure tracking correlations corrected for within-person variability. Statistics in Medicine, 1992, 11, 1187-1194.	1.6	22
169	Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually. Journal of the National Cancer Institute, 1989, 81, 1879-1886.	6.3	2,934
170	PHYSICOCHEMICAL DIFFERENCES BETWEEN FRAGMENTS OF PLASMA MEMBRANE AND ENDOPLASMIC RETICULUM. Journal of Cell Biology, 1966, 30, 601-621.	5.2	76